7.23.2020. Cornerstone Government Affairs COVID-19 Legislative Update

Legislation
Supplemental IV
Timeline: After a couple fire drills between the White House and Senate Republicans, Leader McConnell said on the Senate floor today that Republicans will be releasing the bill early next week . He indicated that various Senate Chairs and other senators will be introducing their portions of the bill on Monday. McConnell had planned to roll out the bill this morning, after reportedly reaching an agreement with the White House last night. However, some last-minute disagreements caused a delay to next week. As there are some difficult sticking points that remain to be worked out between Democrats and Republicans, negotiations will not be quick and painless – there’s no guarantee that the bill is negotiated before the July 31 unemployment insurance expiration. Last week, House Majority Leader Hoyer told members to keep the first week of August open, though now there is talk of voting during the second week of August. The Paycheck Protection Program expires on August 8.
 
Politics/Process: Republicans have been working to reach consensus over the past week, but the past two days have shown the most volatility. There were reports of Leader McConnell proposing the extension of the enhanced unemployment insurance (UI) for four months at a lower rate of $450 per week, separate from a larger package. The White House reportedly rejected that idea. Severing the UI portion of the package would take significant pressure off lawmakers to get this done quickly. Late last night the White House and Senate Republicans had reportedly reached a deal and McConnell was set to roll it out at 9:30am this morning, but that plan was quickly changed and the roll out was delayed to next week. While the plan is to begin releasing the package in pieces on Monday, we could see another delay if consensus isn’t reached. Some committees had already finished drafting text, while others may still be in process. 
 
Until Republicans introduce a bill, Democrats are in no hurry to begin negotiating with themselves . Minority Leader Schumer and Speaker Pelosi have been in constant conversation and will likely remain so. As Republicans will need 60 votes to pass the bill through the Senate, Democrats will have significant leverage once negotiations begin. Senate Majority Whip John Thune has indicated that when this is all said and done, he may lose as many as 25 Republicans on the final vote.
 
Policy: While text has yet to be finalized and there could be significant changes from now until Monday , the following represents what the White House and Senate Republicans had agreed to as of last night (agreement here ):

  • Extension of the enhanced unemployment insurance , though there will be a transition period of beneficiaries receiving a flat amount (less than $600 per week) then moving to a different policy that disallows beneficiaries from receiving more in the benefit than their previous income.
  • Extension of the Paycheck Protection Program including:
    • A second round of PPP loans for business that have 1) fewer than 300 workers, OR 2) are within an SBA-designated size threshold for their industry and can show 50% or more in lost revenue.
    • Streamlined forgiveness for loans under $150k.
    • Forgiveness to include other costs like riot damage, supplier costs, and other expenses.
    • Working capital loan for businesses with fewer than 300 workers (as an alternative to PPP).
  • Liability protections for organizations that mandate plaintiffs show defendants were grossly negligent/engaged in willful misconduct AND violated public health guidelines.
  • No funding for state, local, tribal, or territorial governments , but states may use the funding to make up lost revenues. Limitations on what states can use funding for (no funds for pensions/rainy-day fund).
  • Tax provisions including,
    • Enhanced employee retention tax credit ,
    • Tax deductions for COVID-related expenses like testing and PPE,
    • Increasing the business meal deduction to 100 percent (from 50 percent).
  • $235 billion for health , including
    • $25 billion for testing,
    • $26 billion for vaccines,
    • $15.5 billion for NIH
    • $25 billion for provider relief fund
    • $15 billion for child chare
    • $4.5 billion for SAMHSA.
  • $105 billion for education including:
    • $29 billion for higher education institutions,
    • $70 billion for K-12 (with schools receiving it within 30 days of enactment, $30 billion of this will be available only to schools that physically reopen).
  • Another round of economic stimulus payment (eligibility and amount TBD).
  • Medicare and Medicaid provisions including:
    • Part B premium freeze until 2022,
    • Extension of telemedicine reimbursement through 2021,
    • Extended timeline for providers to repay Medicare Advances.
  • $302 billion for appropriations including:
    • $235 billion for Labor HHS (referenced above),
    • $20 billion Agriculture,
    • $21.3 billion for Defense ($11 billion for 3610 payments),
    • $13 billion for THUD,
    • ~$3 billion for Homeland (almost $1 billion for FEMA grants, $1.6 billion to CBP),
    • $5 billion for SFOPS.

Democrats have continued to roll out new proposals (Sen. Wyden and Leader Schumer proposal on unemployment insurance, white papers on health care and testing) and highlight various provisions from the Heroes Act. Beyond extending unemployment insurance, funding for state/local/tribes, and funding for education and health, Democrats have been highlighting many other issues, including rental assistance and supporting communities of color , which have been disproportionately impacted by the virus.
 
The House passed the Democrats’ opening bid for the next bill, the Heroes Act, on May 15. While it’s been over two months since House passage of the bill and the contours of the debate and which issues are most pressing have shifted slightly, it can still serve as a marker of what Senate Republicans will be responding to in their bill. Heroes Act text (as of 5/12/2020) here. Section by section here. One pager here. State and Local one pager here. NCAI’s summary on tribal provisions here. Manager’s amendment here. House Rules Committee report here.
 
Passed Legislation
Moving forward, this section will only include new information and guidance. For past information and guidance and legislation, please refer to the archives. For a summary of all supplementals, please see here.
 
New Implementation Information and Guidance

  • 7/21 – Treasury and SBA released new data on the Paycheck Protection Program and Economic Injury Disaster Loans (EIDL) and EIDL Advance programs. PPP data here. EIDL data here. EIDL Advance data here.
By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS